In what the
Biotechnology Innovation Organization (BIO) is calling a “monumental campaign to combat, and hopefully eradicate, COVID-19,” it’s become evident that small, creative-thinking biotech companies are needed to help lead on the frontline..
Through our joint initiative,
BLUE KNIGHT™, the Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson Innovation – JLABS (JLABS) are collaborating with early-stage companies with the goal of bringing leading ideas to patients. By building the
Blue Knight community, we aim to be better prepared with even more deployable potential solutions when the next health threat strikes. To do so, we are challenging you, commercial innovators, to explore multi-use opportunities for your technologies that may help shift the paradigm of preparedness and rapid health threat response.
Multi-use technology* models provoke innovators to think outside the box when conceptualizing market impact. Rather than developing a narrow concept that addresses one commercial need, multi-use technologies have the potential to address multiple gaps. One of the potential utilizations may be a medical countermeasure (MCM)—a product that
may be used during or in response to a potential public health threat. Multi-use technologies can help us move out of the “one bug-one drug” mindset towards nimble and more sustainable models of innovation that are capable of addressing routine health needs and have the potential toquickly adapt to a public health threat.
Blue Knight companies exemplifies the types of potential multi-use solutions we aim to support, including wearable detection devices and platform technologies that may help address emerging infectious disease needs, as well as support broader disease areas.
In response to the COVID-19 pandemic, we’ve seen many innovators
pivoting or repurposing existing science and technologies to address MCM needs. In 2020, for example, Johnson & Johnson Innovation worked with over 100 global innovators to explore COVID-19
applications for their approaches. While pivoting can help further our repertoire of pandemic solutions, it must happen more proactively because, in emergencies, it’s often the solutions with proven efficacy and safety that can be rapidly scaled to meet new manufacturing demands and deployed in unprecedented timeframes.
For companies already innovating with the aim to address infectious pathogens, pivoting for pandemic preparedness may not be a far stretch. However, if you’re focusing outside the realm of infectious disease, identifying a preparedness utility may require creativity and unorthodox thinking.
While we need solutions for combatting specific threats, it’s also critical to develop end-to-end technologies that may be foundational for improving patient care and responsiveness across routine health challenges. One great example is the
safety syringe: a high-performance, retractable needle that evolved in response to an increasing incidence of needle-stick injures among medical professionals. They aren’t often at the forefront when discussing the extraordinary ideas supporting our COVID-19 response, but if the manufacturing supply chain did not already exist and providers were not already trained to use them, the vaccine rollout could have looked very different.
It’s these end-to-end solutions invested in years ago, like the safety syringe, that are now the tools helping us cross the finish line in addressing COVID-19.
Looking to the future, it may be the innovations of today that become the solutions for
Blue Knight aims to shift the paradigm of health threat preparedness by developing a rich pipeline of science and technology solutions that can address the innovation gaps. Together, we hope to establish promising technologies now, so that they become the critical tools waiting in our toolbox to deploy during the health threat.
Let’s start reimagining possibilities together:
sign up to meet with us!
Disclaimer: The content covered in this blog is intended for educational and informational purposes only and may contain opinions by persons and organizations not affiliated with Johnson & Johnson Innovation LLC, and/or its parent or affiliated companies (hereinafter collectively referred to as "JJI"). JJI makes no representations, warranties, express or implied, as to the content, the views, advice, or the information presented. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of JJI, Johnson & Johnson or its affiliates.
Acknowledgement: This blog was developed as a collaboration between BARDA and Johnson & Johnson Innovation – JLABS and is also published on HLTH Matters Blog.